Valuation: Avalo Therapeutics, Inc.

Market Cap 393M 351M 322M 293M 549M 37.19B 563M 3.85B 1.55B 19.63B 1.47B 1.44B 62.21B P/E 2026 *
-2.59x
P/E 2027 * -2.61x
Enterprise Value -31.43M -28.08M -25.79M -23.42M -43.99M -2.98B -45.09M -308M -124M -1.57B -118M -115M -4.98B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.31%
Yield 2026 *
0.16%
Yield 2027 * 0.01%
1 day-0.34%
1 week+7.26%
Current month+0.98%
1 month-50.41%
3 months-59.89%
6 months-47.46%
Current year-60.13%
1 week 6.66
Extreme 6.66
7.71
1 month 6.53
Extreme 6.53
15.09
Current year 6.53
Extreme 6.53
24.27
1 year 6.53
Extreme 6.53
24.27
3 years 3.39
Extreme 3.39
34.46
5 years 3.39
Extreme 3.39
7,027.15
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/9/26 Free

Director

1,322 0.0025%
30/9/26 Free

Director

1,109 0.0021%
30/9/26 Free

Director

1,352 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%+7.26%-56.57%-70.80% 393M
-2.43%-7.34%+36.10%+58.44% 62.23B
+0.61%+0.77%+11.13%+69.42% 54.92B
+0.62%+2.58%+20.96%+98.18% 55.26B
+1.54%-3.47%+22.55%+32.92% 42.59B
-1.87%-2.99%+13.87%+93.23% 41.08B
+3.21%+4.52%+228.05%+778.32% 40.33B
+0.57%+24.09%+99.46%+84.11% 33.12B
-1.09%-0.05%+13.55%+45.35% 32.61B
-4.21%+11.31%-43.24%+325.35% 23.98B
Average -0.33%+4.18%+34.59%+151.45% 38.65B
Weighted average by Cap. -0.19%+2.12%+45.07%+159.21%

Financials

2026 *2027 *
Net sales - -
Net income -111M -99.49M -91.39M -83M -156M -10.55B -160M -1.09B -439M -5.57B -418M -409M -17.65B -139M -124M -114M -103M -194M -13.12B -199M -1.36B -546M -6.93B -520M -509M -21.95B
Net Debt -424M -379M -348M -316M -593M -40.16B -608M -4.15B -1.67B -21.2B -1.59B -1.56B -67.19B -306M -273M -251M -228M -428M -28.94B -438M -2.99B -1.2B -15.28B -1.15B -1.12B -48.42B
Projected Income Statement - Annual - Avalo Therapeutics, Inc.
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Employees
33
Date Price Change Volume
04/11/26 USD 7.240 -1.09% 1,344,922
02/11/26 USD 7.320 +2.09% 1,618,575
30/10/26 USD 7.170 -3.63% 1,534,540
29/10/26 USD 7.440 +4.49% 2,274,214
28/10/26 USD 7.120 +5.48% 2,167,454
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avalo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
7.320USD
Average target price
36.60USD
Spread / Average Target
+400.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Avalo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AVTX Stock